Core Insights - Rocket Doctor AI Inc. reported its first significant revenue quarter in Q2 2025, generating $0.5 million, primarily due to the acquisition of Rocket Doctor Inc. [5][6] - The company completed the acquisition of Rocket Doctor Inc. on April 10, 2025, enhancing its digital health platform and expanding its operational capabilities [4][12] - The company is focusing on U.S. expansion and has secured new contracts, including a virtual-care partnership with Central California Alliance for Health, serving approximately 450,000 members [5][23] Financial Highlights - Q2 2025 revenue was $0.5 million, compared to $0 in Q1 2025 and Q2 2024, marking a significant increase attributed to the Rocket Doctor acquisition [6] - Gross margin for Q2 2025 was 89%, a notable improvement from 0% in previous quarters, driven by revenue from the digital health platform [6][27] - The net comprehensive loss for Q2 2025 was $2.7 million, or $0.04 per share, consistent with the loss reported in Q1 2025 but an improvement from $2.7 million or $0.07 per share in Q2 2024 [6][27] Corporate Developments - The company has shifted its business model from B2C to B2B, aligning with the demand for AI-driven solutions in healthcare systems and academic institutions [8] - The Global Library of Medicine (GLM) is central to the company's strategy, providing clinical decision support and educational tools [7][21] - The company has made significant investments in enhancing its platform architecture and API capabilities, positioning itself for accelerated commercialization [24] Market Opportunity - The global AI healthcare market is projected to exceed USD $180 billion by 2030, driven by the demand for efficiency and accuracy in clinical workflows [9] - The conversational AI segment is expected to grow from approximately USD $13.5 billion in 2024 to between USD $49 billion and $123 billion by 2030, indicating a ~24% CAGR [9] Product Development - The Medical Education Suite (MES) was successfully deployed to 240 medical students at the University of Minnesota, showcasing the potential of AI-driven tools in medical education [15][24] - Rocket Doctor's technology solutions, including Starship EMR and RD Connect, are designed to streamline workflows and reduce care delivery costs [12][19] - The company is actively developing an AI Pharmacy Assistant, with integration plans involving over 20 pharmacies [18]

Key Takeaways HIMS adds Europe via ZAVA acquisition, eyes Canada in 2026 with weight-loss-focused expansion.HIMS hit 2.4 million subscribers in Q2 2025, with 30.8% year-over-year growth and rising per-user revenue.AMWL boosts software to 57.1% of revenue, aided by its MHS contract expansion.Virtual healthcare is rapidly evolving, with Hims & Hers Health, Inc. (HIMS) and American Well Corporation (AMWL) , popularly known as Amwell, at the forefront. HIMS is a consumer-focused digital health platform that off ...

Led by Prof. Dr. Marianne Brodmann, PI of clinical studies for the Lumee™ Oxygen CE Mark, collaboration includes practice adoption and platform integration in cases and clinical study programs BERKELEY, Calif, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces a commercial and clinical collabora ...

Core Viewpoint - PAVmed Inc. has formed a new subsidiary to license advanced endoscopic imaging technology from Duke University, aimed at improving the diagnosis and treatment of esophageal dysplasia, which is a precursor to esophageal cancer [1][8]. Group 1: Technology and Collaboration - The technology involves a multi-modality probe that combines angle-resolved low coherence interferometry (a/LCI) with optical coherence tomography (OCT), potentially offering a more efficient alternative to traditional biopsies [1]. - PAVmed will collaborate with Lucid Diagnostics as a strategic and equity partner in this initiative [1]. - The technology is expected to enable real-time detection and immediate treatment of dysplasia during endoscopic procedures, addressing the limitations of traditional biopsy methods [3][6]. Group 2: Clinical Implications - Dr. Nicholas Shaheen highlighted that this technology could transform the diagnosis and treatment of esophageal precancer, improving patient outcomes and healthcare resource utilization [2]. - Prior clinical research indicated that the a/LCI technology demonstrated 100% sensitivity and 88% overall accuracy in detecting precancerous changes during live examinations [6]. - The integrated a/LCI and OCT technology has shown comparable sensitivity and improved specificity for detecting dysplasia, with results pending peer-reviewed publication [6]. Group 3: Company Strategy and Market Potential - PAVmed's CEO, Dr. Lishan Aklog, expressed optimism about the commercialization of this technology, anticipating that widespread adoption will significantly increase the diagnosis of esophageal precancer [7]. - The venture aligns with PAVmed's structure of independently financeable subsidiaries and builds on successful partnerships with academic medical centers [8]. - The exclusive worldwide license agreement for the a/LCI + OCT technology is contingent upon the execution of a definitive license agreement [8].

NEW YORK, Aug. 25, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced that a reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share (the "Common Stock") at a ratio of 20-for-1 is expected to be implemented at market open on August 28, 2025. The Company's Common Stock will begin trading on the Nasdaq Capital Market on a post-split basis at the market open on August 28, 2 ...

Core Viewpoint - Rocket Doctor AI Inc. has successfully closed a non-brokered private placement, raising a total of C$4,234,700 through the issuance of special warrants and units, which will support its expansion plans in the U.S. market [1][2]. Group 1: Offering Details - The company closed a private placement of 3,677,400 special warrants at C$0.50 each, raising C$1,838,700, and 4,792,000 units at the same price, raising C$2,396,000 [1]. - Each unit consists of one common share and one share purchase warrant, with the warrant exercisable at C$0.75 for 12 months [2]. - The special warrants will convert into units automatically on the earlier of the filing of a prospectus supplement or four months and one day after issuance [3]. Group 2: Financial Use and Fees - Proceeds from the offering will be allocated for sales and administrative expenses, software research and development, and working capital [5]. - The company paid finder’s fees totaling C$201,616 and issued 403,232 broker warrants, each allowing the purchase of one share at C$0.75 for 12 months [4]. Group 3: Company Overview - Rocket Doctor AI Inc. provides AI-powered healthcare solutions, aiming to enhance access to quality healthcare through its proprietary technology, including the Global Library of Medicine [8]. - The company has facilitated over 700,000 patient visits through its platform, empowering physicians to manage their practices more efficiently [8]. - The focus is on reaching underserved communities in Canada and supporting patients on Medicaid and Medicare in the U.S. [9].

Core Insights - Profusa, Inc. has made significant leadership additions, appointing Peter O'Rourke as lead independent director and Fred Knechtel as Chief Financial Officer, coinciding with its business combination with NorthView Acquisition Corp [1][2] - The company is positioned at a critical juncture as it prepares to launch its innovative biosensor platform into global markets, with leadership experience expected to drive growth and commercialization [2][3] Leadership Background - Peter O'Rourke has extensive experience in overseeing large healthcare systems, having managed over 1,300 facilities serving more than 9 million veterans during his tenure as Acting U.S. Secretary of Veterans Affairs [2][3] - Fred Knechtel brings a wealth of experience in finance and operations, having worked with various companies across multiple industries, including life sciences and automotive, guiding them through profitable growth and capital restructuring [3][4] Company Overview - Profusa is a digital health company focused on developing tissue-integrated sensors that provide continuous, actionable medical data, aiming to deliver personalized biochemical signatures for both personal and medical use [4] - The company emphasizes the affordability and long-lasting nature of its injectable biosensors, which are designed to be reliable for clinicians [4]

VANCOUVER, British Columbia, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the "Company" or "Treatment") is pleased to announce that it is rebranding and reincorporating as Rocket Doctor AI Inc. This milestone reflects the Company's continued evolution and its commitment to advancing its strategic vision. Concurrently with the completion of the proposed name change, the Company's trading symbol on the Canadian Securities Exchange will be changed from "TRUE" ...

Lucid processed 2,756 EsoGuard® 2Q25 tests, recognized revenue of $1.2 million, and secured CAC meeting on Medicare LCD for EsoGuard to be held on September 4 Veris Health completed 2Q25 financing, relaunched development of implantable physiological monitor, and initiated integration steps to launch commercial phase with OSU-The James Conference call and webcast to be held today, August 14, at 8:30 AM EDT NEW YORK, Aug. 14, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diver ...

Core Insights - Hims & Hers Health, Inc. (HIMS) has faced short-term stock losses, declining 21.3% while the industry rose by 1.7% [1] - The company reported strong second-quarter 2025 results, with significant growth in subscribers and online revenue [2][9] - HIMS anticipates third-quarter 2025 revenues between $570 million and $590 million, reflecting a year-over-year increase of 42-47% [7] Financial Performance - HIMS experienced a 30.8% growth in subscribers, reaching 2.4 million, and a 29.8% increase in monthly online revenue per subscriber to $74 [10] - The gross margin contracted by 491 basis points due to rising product costs, which is a concern for future profitability [9][15] - The company’s revenue guidance for the full year 2025 is set at $2.3 billion to $2.4 billion, with an EBITDA outlook of $295 million to $335 million [11] Strategic Developments - HIMS completed an $870 million convertible senior notes offering to support global expansion and AI-led innovation [12] - The company plans to launch a weight loss program in Canada in 2026, aiming to capture market share in an underserved segment [13] - HIMS acquired ZAVA, a European digital health platform, enhancing its geographic reach and service offerings [14] Market Position - HIMS' forward 12-month price-to-sales (P/S) ratio is 4X, lower than the industry average of 5.5X but higher than its three-year median of 2.3X [16] - Estimates for HIMS' 2025 earnings have decreased by 12.3% to 64 cents in the past 60 days [19] - The company maintains a favorable growth outlook, supported by a strong business model and financial stability [22]